| Dr Peter B Lucas, MD | |
|
10191 Ne Beach Crest Dr, Bainbridge Island, WA 98110-1368 | |
| (206) 713-8713 | |
| (066) 738-2612 |
| Full Name | Dr Peter B Lucas |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 10191 Ne Beach Crest Dr, Bainbridge Island, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811052897 | NPI | - | NPPES |
| 8196461 | Medicaid | WA | |
| 00031243 | Other | WA | MEDICAL LICENSE |
| G50158 | Other | CA | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD00031243 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Peter B Lucas, MD 10191 Ne Beach Crest Dr, Bainbridge Is, WA 98110-1368 Ph: (206) 713-8713 | Dr Peter B Lucas, MD 10191 Ne Beach Crest Dr, Bainbridge Island, WA 98110-1368 Ph: (206) 713-8713 |
News Archive
Researchers at Henry Ford Hospital compared the patient population of a major U.S. prostate cancer study with patients found in three U.S. cancer databases, ultimately finding the patients of the study to be inconsistent with the average prostate cancer patient.
Mevion Medical Systems, Inc., a radiation therapy company dedicated to advancing the treatment of cancer, announced today that it has received FDA 510(k) clearance for its MEVION S250 Proton Therapy System.
Dr. Reddy's Laboratories announced the initiation of dosing with DRL-17822 in patients with diagnosis of type II dyslipidemia. DRL-17822 is a selective, orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), for the treatment and/or prevention of dyslipidemia, atherosclerosis and associated cardiovascular disease.
Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA - a leading company in conducting early-stage discovery research programs for the life science industry - to develop new treatments for two autoimmune diseases, multiple sclerosis (MS) and type 1 diabetes (T1D).
A team of scientists at Florida Atlantic University has uncovered a brain-signaling pathway that can be pharmacologically manipulated in genetically engineered mice to reverse an autism-related pathway.
› Verified 3 days ago
Dr. Kathryn Margaret Rahn, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 793 Ericksen Ave Ne, Suite 123, Bainbridge Island, WA 98110 Phone: 206-855-8890 Fax: 206-855-8864 | |
Bridget Russell Carnahan, DO Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 159 Wyatt Way Ne, Bainbridge Island, WA 98110 Phone: 206-596-0974 | |
Dr. Ellen Violet Michael, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 345 Knechtel Way Ne, Ste. 102, Bainbridge Island, WA 98110 Phone: 206-780-6779 Fax: 206-780-7923 | |
James Oscar Raney, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 271 Wyatt Way Ne, #204, Bainbridge Island, WA 98110 Phone: 206-855-9600 Fax: 206-855-9600 |